Home
News
Create
Screeners
Insights
Fabino Enterprises
20.
31
0.00
(0.00%)
Market Cap
₹4.30 Cr
PE Ratio
-7.64
Industry
Healthcare
Buy
Sell
Company Performance:
1D
0.00%
1M
0.00%
6M
-24.78%
1Y
-17.94%
5Y
-49.67%
View Company Insights
Latest news about Fabino Enterprises
Fabino FY26 Net Loss Rs 35.97 Cr, Revenue Declines
May 23, 2026
Fabino Enterprises announced its audited financial results for the year ended March 31, 2026, reporting a consolidated net loss of ₹55.87 crore compared to a net profit of ₹6.11 crore in the previous year. Standalone net loss was ₹35.97 crore, with revenue from operations falling to ₹114.28 crore from ₹180.36 crore in FY25. Key audit matters included write-offs of trade receivables and expired inventory.
Open Offer for 26.00% Stake in Fabino Enterprises Limited at ₹20 Per Share by R G Family Trust, Sameer Gupta and Sundeep Gupta
May 13, 2026
Fabino Enterprises Open Offer for 26% Stake at ₹20/Share Scheduled June 22–July 06, 2026
May 06, 2026
Fabino Enterprises Ltd. Confirms Non-Applicability of SEBI Large Corporate Framework for FY2027
Apr 11, 2026
Fabino Enterprises Ltd. Submits Q4FY26 Compliance Certificate to BSE
Apr 11, 2026
More news about Fabino Enterprises
10
Apr 26
Sushma Shekhar Acquires 8.29% Stake in Fabino Enterprises Through Open Market Purchase
Sushma Shekhar acquired 174,000 shares (8.29%) of Fabino Enterprises Ltd. through open market purchase on April 9, 2026. The acquirer, who is not part of the promoter group, previously held no shares in the BSE-listed company. The acquisition has been disclosed under SEBI Regulation 29, with the company's equity capital remaining at INR 2,10,00,000 divided into 21,00,000 shares of INR 10 each.
26
Dec 25
Fabino Enterprises Independent Director Mr. Kuldeep Solanki Resigns with Immediate Effect
Fabino Enterprises Limited announced the immediate resignation of Non-Executive Independent Director Mr. Kuldeep Solanki (DIN: 07109951) effective December 26, 2025, citing pre-occupation and personal commitments. The company has informed BSE Limited under Regulation 30 of SEBI Listing Regulations and confirmed that succession planning will be addressed in the upcoming Board meeting.
26
Dec 25
Fabino Enterprises Appoints Deepali Singla as Independent Director
Fabino Enterprises Limited has appointed Mrs. Deepali Singla (DIN: 11442242) as Additional Non-Executive Independent Director effective December 26, 2025, following a board meeting. She brings over six years of professional experience as an Associate at United Lex, specializing in document review, legal research, and regulatory compliance with exposure to Supreme Court and Delhi High Court proceedings.
Fabino Enterprises
20.
31
0.0
(0.0%)
1 Year Returns:
-17.94%
Industry Peers
Sun Pharmaceutical
1,788.50
(-
0.
08
%)
Divis Laboratories
6,576.50
(+
0.
67
%)
Torrent Pharmaceuticals
4,368.50
(+
1.
17
%)
Cipla
1,375.20
(-
0.
30
%)
Zydus Life Science
1,076.60
(-
0.
16
%)
Dr Reddys Laboratories
1,263.30
(-
0.
84
%)
Lupin
2,261.20
(+
0.
51
%)
Mankind Pharma
2,369.50
(+
3.
07
%)
Aurobindo Pharma
1,440.40
(+
0.
78
%)
Laurus Labs
1,394.30
(+
0.
85
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar